Latest Operational Scalability News

Adheris Health’s revenue and profit fell sharply in Q4 FY26 due to the previous challenging pharma budget cycle, but the company achieved cashflow break-even and ended the period with $9.5 million in net cash.

Boss Energy has delivered on its revised FY26 uranium production guidance with 1.41 million pounds of U3O8 and accelerated its feasibility study for the Honeymoon project, aiming to unlock future growth with a new life-of-mine plan by August 2026.

Neurizon Therapeutics has secured a critical five-year supply agreement with Elanco Animal Health for GMP-grade monepantel, underpinning the commercialisation readiness of its lead ALS drug candidate NUZ-001.

Smartgroup posted robust 2025 results with record customer growth and accelerated EV leasing, backed by strategic digital investments and a $20 million share buy-back plan following fleet portfolio sales.

Anson Resources and POSCO Holdings have sealed a binding deal for a $7.2 million lithium extraction demonstration plant at Green River, advancing the project from concept to operational validation.

Aquirian Limited has secured $8 million through a strongly supported placement to accelerate growth of its Drillforce business and support a major $48 million contract at the Lord Byron mine.

Macquarie Bank Limited has posted a robust FY2026 result, with net profit attributable to ordinary equity holders soaring 74% to AUD 6.011 billion, underpinned by strong performances in its Banking and Financial Services and Commodities and Global Markets divisions.

EVE Health Group has appointed Ben Rohr as CEO, shifting Damian Wood to focus on regulatory and clinical affairs, aiming to sharpen commercial execution amid ongoing product rollouts.

QuickFee reported a 9% normalised revenue decline in Q3 FY26, driven by US finance weakness post-US Pay Now sale, while Australian legal disbursement funding surged, underpinning confidence in FY26 earnings guidance.

AI-Media Technologies has reported a robust first half of FY26, achieving an 80% increase in annual recurring revenue driven by its LEXI suite and unveiling a new Hardware as a Service model set to transform its business.

Star Combo Pharma reported a 23% decline in revenue to $11.9 million for the half year ended December 2025, driven by the loss of a major OEM contract and closure of its AustoYou retail business. Despite this, operating profit after tax rose 49% to $413,243, reflecting effective cost management.

Aeeris Ltd has reported a return to profitability for the half-year ended December 2025, driven by a strategic restructure and the launch of its AWARE platform. The company also secured new customers and strengthened its technology-led revenue streams.